首劑疫苗接種率破八成 林鄭:本周內公布「疫苗通行證」詳情
行政長官林鄭月娥在社交網頁宣布,本港接種首劑新冠疫苗的合資格人口突破八成,當中撇除近日才納入計劃的5至11歲兒童。她表示,接種率仍然受制於部分市民,特別是長者對疫苗猶豫,為盡快達到九成或以上的目標,政府很快會修訂相關規例,落實「疫苗通行證」的要求,屆時沒有打針的人士將須面對進入很多處所和出席活動的限制。
林鄭月娥指,「疫苗通行證」將於2月24日實施,政府將於本周內公布詳情,呼籲還未接種第一劑疫苗的市民,特別是長者,把握未來兩個多星期的機會去接種,否則日常生活便會面對諸多不便和限制,為方便處所核對市民的疫苗接種紀錄,最新版本的「安心出行」流動應用程式已經上架,讓市民下載或更新到這版本。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.